SCHEMBL13352016

SCHEMBL13352016

COc1ccc(/C=C/C(=O)Nc2ccccc2C)cc1OC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.74
KMT2A Q03164 4/20 0.74
HPGD P15428 4/20 0.74
ALDH1A1 P00352 3/20 0.74
SMN1; SMN2 Q16637 3/20 0.74
TP53 P04637 2/20 0.74
CYP3A4 P08684 2/20 0.74
HIF1A Q16665 2/20 0.74
PKM P14618 2/20 0.74
NPC1 O15118 2/20 0.74
RAB9A P51151 2/20 0.74
CYP1A2 P05177 2/20 0.74
MAPK1 P28482 2/20 0.74
NPSR1 Q6W5P4 2/20 0.74
KDM4E B2RXH2 2/20 0.74
CYP2C9 P11712 1/20 0.74
CYP2C19 P33261 1/20 0.74
HSD17B10 Q99714 1/20 0.74
ABCC4 O15439 1/20 0.74
HPGDS O60760 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL297188 1.00 MEN1 (0.74) MEN1KMT2AHPGDALDH1A1SMN1; SMN2
SCHEMBL13352117 0.92 MMP1 (0.67) MEN1KMT2AHPGDALDH1A1SMN1; SMN2
SCHEMBL13352028 0.90 KDM1A (0.82) MEN1KMT2AHPGDALDH1A1SMN1; SMN2
SCHEMBL13352026 0.90 MMP1 (0.75) MEN1KMT2AHPGDALDH1A1SMN1; SMN2
SCHEMBL26215467 0.90 PKM (0.62) MEN1KMT2AHPGDALDH1A1SMN1; SMN2
SCHEMBL296725 0.90 SMN1; SMN2 (0.77) MEN1KMT2AHPGDALDH1A1SMN1; SMN2
SCHEMBL13352119 0.89 KDM1A (0.68) MEN1KMT2AHPGDALDH1A1SMN1; SMN2
SCHEMBL13352145 0.89 MEN1 (0.66) MEN1KMT2AHPGDALDH1A1SMN1; SMN2
SCHEMBL13352144 0.89 MEN1 (0.71) MEN1KMT2AHPGDALDH1A1SMN1; SMN2
SCHEMBL13352033 0.88 APP (0.64) MEN1KMT2AHPGDALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130497-A1 Therapeutic Compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130497-A1 Therapeutic Compounds NFATC1, NAT1, AADAC MEN1 2640/4885KMT2A 1798/4885HPGD 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.